Opana ER 30mg: Product Information and Safety Guide

Opana ER 30mg is an extended-release formulation of oxymorphone hydrochloride, a prescription opioid pain medication. It was historically indicated for managing severe, persistent pain when continuous, around-the-clock opioid treatment was required and alternative options were inadequate. Oxymorphone is a potent opioid associated with serious risks, including respiratory depression, overdose, physical dependence, and addiction.

Opana ER 30mg: Active Ingredient and Medical Background

The active ingredient in Opana ER 30mg is oxymorphone hydrochloride. It acts on opioid receptors in the central nervous system to change how the body perceives pain. The extended-release formulation was designed to release the medication over time rather than provide immediate relief for occasional discomfort.

Opioid treatment is not appropriate for every pain condition. Healthcare professionals consider the underlying diagnosis, previous treatments, medical history, other medicines, and individual risk factors before deciding whether opioid therapy is suitable. The strength shown in a product name is not a recommendation for an individual patient.

Opana ER 30mg: Understanding Extended-Release Tablets

Extended-release medicines have different release characteristics from immediate-release formulations. These products should not be substituted for one another without professional assessment. Differences in formulation can affect how medication is released and absorbed by the body.

Extended-release opioid tablets must be handled according to their specific instructions. Crushing, chewing, breaking, or dissolving an opioid tablet can release medication too rapidly and cause a potentially fatal overdose. Never alter a tablet or change how a prescription medication is taken without guidance from a pharmacist or prescriber.

Opana ER 30mg: Prescription Oversight

Oxymorphone treatment requires an individualized medical evaluation. A healthcare professional considers the severity and duration of pain, previous opioid exposure, existing medical conditions, other medications, and the risks associated with opioid therapy.

Patients should not begin opioid treatment, change a dose, or switch between opioid products based on online product descriptions. Regular opioid use can cause physical dependence, and suddenly stopping treatment may lead to withdrawal symptoms. Any treatment change should be planned with the prescribing professional.

Opana ER 30mg: Side Effects and Serious Risks

Possible side effects associated with oxymorphone include nausea, vomiting, constipation, dizziness, drowsiness, itching, and lightheadedness. These effects may interfere with concentration, balance, and everyday activities. Driving or operating machinery can be unsafe when alertness is impaired.

Serious risks include respiratory depression, low blood pressure, addiction, misuse, and overdose. Alcohol, benzodiazepines, sleeping medications, and other central nervous system depressants can increase sedation and the risk of dangerously slowed breathing. Avoid alcohol and consult a healthcare professional before combining opioid medication with other sedating substances.

Seek emergency medical assistance if someone becomes unresponsive, is difficult to awaken, or develops slow, shallow, or absent breathing. Naloxone can temporarily reverse an opioid overdose, but emergency medical care is still necessary.

Opana ER 30mg: Precautions and Safe Storage

Before opioid treatment, patients should disclose breathing disorders, liver conditions, gastrointestinal problems, head injuries, pregnancy, and all prescription medicines, nonprescription products, and supplements they use. These factors can affect treatment safety.

Keep opioid medication securely stored in its original packaging, away from children and anyone for whom it was not prescribed. Accidental ingestion can be fatal. Follow pharmacist guidance for safe storage and disposal, and ask a healthcare professional whether naloxone should be available.

Opana ER 30mg: Discontinued Product Status

The branded Opana ER formulation was voluntarily withdrawn from the U.S. market in 2017 following FDA concerns about the public health consequences of abuse. Its approval was subsequently withdrawn. The FDA had previously distinguished the discontinuation of the original formulation from withdrawal for reasons of safety or effectiveness; this does not establish that the reformulated product is currently available.

Availability and regulatory status can differ between formulations and jurisdictions. Consult a licensed pharmacist or prescriber to verify current treatment options. Do not rely on a historical product listing as confirmation of present-day availability.

Medical disclaimer: This description is for educational purposes only. It does not replace official prescribing information, individualized medical advice, or a treatment plan from a qualified healthcare professional.